Giuseppe Ciaramella

This inventor holds 57 USPTO granted patents and 51 published patent applications and 6 EPO patents, primarily in RNA Vaccines. Top assignees: Modernatx, Inc., Ares Capital Corporation, as Agent, Vanderbilt University. Active years: 2018-2026.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Giuseppe Ciaramella. Retrieved from https://idiyas.com/inventor/giuseppe-ciaramella

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 57 (Patent Applications = 51)

% Patents Active = 100.0

EPO Patents = 6 (Patent Applications = 37)

Average Co-Inventor Count = 2.2

ph-index = 20

Forward Citations = 1,413(Granted Patents)

Forward Citations (Not Self Cited) = 826(Dec 10, 2025)

Company Filing History:

Ares Capital Corporation, as Agent

patents

1 out of 1,221

Vanderbilt University

patents

where one patent can have more than one assignee

Years Active: 2018-2026

Loading Chart...

Areas of Expertise:

Betacoronavirus

RNA Vaccines

Influenza

RSV

Nucleic Acid

Zoonotic Diseases

Chikungunya

Human Cytomegalovirus

Vaccines

VZV

Broad Spectrum

Polynucleotides

57 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12629412 - BETACORONAVIRUS mRNA VACCINES (2026-05-19),

2. 12622960 - VARICELLA ZOSTER VIRUS (VZV) VACCINE (2026-05-12),

3. 12551734 - BETACORONAVIRUS mRNA VACCINES (2026-02-17),

4. 12521577 - BETACORONAVIRUS RNA VACCINES (2026-01-13),

5. 12453766 - RSV RNA vaccines (2025-10-28),

6. 12409347 - Betacoronavirus mRNA vaccines (2025-09-09),

7. 12409218 - Influenza vaccine (2025-09-09),

8. 12403336 - Betacorona virus mRNA vaccines (2025-09-02),

9. 12403335 - Betacoronavirus MRNA vaccines (2025-09-02),

10. 12329812 - Nucleic acid vaccines (2025-06-17),

11. 12318443 - Influenza vaccine (2025-06-03),

12. 12274743 - Nucleic acid vaccines (2025-04-14),

13. 12208288 - Betacoronavirus RNA vaccines (2025-01-28),

14. 12150980 - Concatemeric peptide epitope RNAs (2024-11-26),

15. 11918644 - Varicella zoster virus (VZV) vaccine (2024-03-05),

Title: Giuseppe Ciaramella: Pioneering Innovator in Biomedical Technology

Introduction:

Giuseppe Ciaramella is a distinguished inventor located in Sudbury, MA (US) known for his remarkable contributions to the field of biomedical technology. With an impressive portfolio of 43 patents, Giuseppe's work has significantly advanced the realm of nucleic acid vaccines.

Latest Patents:

Among his recent patents is the Varicella zoster virus (VZV) vaccine, focusing on nucleic acid vaccines containing RNA polynucleotides encoding VZV antigens. Additionally, he has made strides in RSV RNA vaccines, utilizing lipid nanoparticles for effective formulation.

Career Highlights:

Giuseppe's career is adorned with impactful endeavors, including his roles at renowned companies like Modernatx, Inc. and Vanderbilt University. At Modernatx, Inc., he played a pivotal role in driving innovation and research in the development of novel vaccine technologies.

Collaborations:

Throughout his career, Giuseppe has collaborated with notable professionals in the industry, such as Sunny Himansu and Eric Yi-Chun Huang. Together, they have worked synergistically to bring forth groundbreaking advancements in the field of biomedical technology.

Conclusion:

In conclusion, Giuseppe Ciaramella emerges as a true visionary and pioneer in the world of innovation, consistently pushing the boundaries of what is achievable in biomedical technology. His dedication to creating a better future through technological advancements is truly commendable, leaving a lasting impact on the landscape of healthcare innovation.

Profile summary based on public USPTO records.